ABSTRACT. The heme oxygenase inhibitor, tin protoporphyrin, is being studied for the prevention of neonatal jaundice. This potential drug, however, is also a photosensitizer that could cause serious and unknown side effects Physiologic jaundice is still being considered a risk factor when administered to newborns. Therefore, we have devel-during the neonatal period. The phenomenon results from the oped in vitro and in vivo procedures for the screening and abrupt cessation of bilirubin clearance by the placenta and a further characterization of potentially safe heme oxygenase transient deficiency in hepatic bilirubin removal. It is exacerbated inhibitors. The ideal inhibitor: 1) contains a biocompatible by the increased rate of bilirubin production in the neonate. metal, 2) is not degraded in tissues, 3) is a highly potent which is 2-to 3-fold greater than that of the adult. Several factors inhibitor of heme oxygenase, and 4) does not participate and conditions further increase this rate (I). In particular, hein photochemical reactions. Proto-and mesoporphyrin de-molytic disease such as ABO and Rh incompatibility cause rivatives with the tin, zinc, manganese, chromium, nickel, significant elevation in total body bilirubin production rates, as and magnesium were screened in vitro for suitability. Chro-indexed by CO excretion rates (2). Markedly elevated serum mium protoporphyrin and mesoporphyrin were further bilirubin concentrations have been associated with neurotoxicity studied in vitro and in vivo and were found to meet the (3). ideal criteria. Chromium mesoporphyrin appeared to be Although the risk factor of moderately elevated serum bilirubin the most potent in vitro inhibitor of adult Wistar rat tissue levels [<20 mg/dL (342 Fmol/L)] in term well babies without heme oxygenase. Four pmol of chromium protoporphyrin hemolysis is being questioned (4). there is less doubt that hyperor chromium mesoporphyrin/kg body weight, administered bilirubinemia in premature infants and in those with hemolytic intraperitoneally to adult male Wistar rats given a heme disease may be deleterious. Traditionally, jaundice is treated load through intraperitoneal administration of 30 pmol through removal of accumulated bilirubin by phototherapy or hemelkg body weight, caused significant suppression of blood-exchange transfusion (5). A potentially more effective and hemolysis-induced increase in carbon monoxide production preventive treatment may be the inhibition of bilirubin producto 72 and 44% of control, respectively, 5.5 h after treat-tion through administration of a specific inhibitor of HO (EC ment. At t = 6 h, the tissue heme oxygenase activity, 1.14.99.3), the rate-limiting enzyme in the bilirubin production measured in vitro, was significantly reduced to 33 and <5% pathway from heme (6, 7). Synthetic analogs of heme, especially in liver and to 22 and <5% in spleen after the administra-the tin and zinc derivatives of PP and MP, have been studied for tion of chromium protoporphyrin and mesoporphyrin, re-this purpose (7-1 1). SnPP has been shown to retard the develspectively, but was not reduced in brain. The results show opment of human neonatal hyperbilirubinemia (8). However. that there exist effective metalloporphyrin heme oxygenase the tin metalloporphyrins have also been shown to be potent inhibitors without photosensitizing properties. compounds.
ment. At t = 6 h, the tissue heme oxygenase activity, 1.14.99.3), the rate-limiting enzyme in the bilirubin production measured in vitro, was significantly reduced to 33 and <5% pathway from heme (6, 7) . Synthetic analogs of heme, especially in liver and to 22 and <5% in spleen after the administra-the tin and zinc derivatives of PP and MP, have been studied for tion of chromium protoporphyrin and mesoporphyrin, re-this purpose (7-1 1). SnPP has been shown to retard the develspectively, but was not reduced in brain. The results show opment of human neonatal hyperbilirubinemia (8) . However. that there exist effective metalloporphyrin heme oxygenase the tin metalloporphyrins have also been shown to be potent inhibitors without photosensitizing properties. (Pediatr photosensitizers capable of producing singlet oxygen (12) . which Res 33: 195-200, 1993) can oxidize a large number of organic molecules, including membrane lipids, energy metabolites, proteins, and nucleic acids ( 1 3, 14) . The destruction of some of these compounds may be Abbreviations responsible for the mortality observed in neonatal rats treated CO, carbon monoxide with photosensitizing metalloporphyrins and subsequently exVeCO, total body C O excretion posed to visible light ( 15, 16) . HO, heme oxygenase Because the potentially serious side effects of this photoreacCrPP, chromium protoporphyrin tivity have been incompletely studied, we have developed the CrMP, chromium mesoporphyrin following criteria and procedures for identification of metalloMnPP, manganese protoporphyrin porphyrins potentially suitable for treatment of human neonatal NiPP, nickel protoporphyrin hyperbilirubinemia. The ideal inhibitor: I ) contains a metal that SnPP, tin protoporphyrin occurs naturally in the body or is harmless in trace amounts, 2) SnMP, tin mesoporphyrin is not degraded in tissue to possibly harmful substances, 3) can PP, protoporphyrin effectively inhibit HO at relatively low (<40 r m~l / k g ) doses. and MP, mesoporphyrin 4) does not participate in photodestructive reactions. In this study. we investigated several synthetic metalloporphyrins with manganese. chromium. nickel. and magnesium as central metals.
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The HO-inhibiting and metabolic characteristics of some of these Supported by National Institutes of Health Grant HD14426 and the Burroughs compounds have been studied by others (7, (17) (18) (19) min. The HO activity in the supernatant was determined by measuring the amount of CO generated by the enzyme from 50 pM/1 1.2 pM methemalbumin in the presence of 1.5 mM NADPH at 37°C in the dark. In vitro inhibition potential of metalloporphyrins was determined by addition of small volumes of metalloporphyrin to the reaction medium (40 pM for the screening procedure and 0.1-40 pM for the in vitro efficacy experiments). The ability of administered metalloporphyrins to inhibit organ HO activity in vivo was determined in the same manner. Tissues used for this purpose were harvested from the same animals used to study metalloporphyrin effects on the in vivo bilirubin production rates (VeCO, see below). HO activity is expressed in terms of nmol CO produced/h/mg protein.
Metalloporphyrin metabolism assay. VrCO. lntraperitoneal heme loading of fasted adult male Wistar rats was used as an iatrogenic model of hyperbilirubinemia. The ability of metalloporphyrins to suppress this exaggerated bilirubin production was determined by measuring the decrease of VeCO (22). Each rat was weighed and then placed in a Plexiglas tube (26 x 5.5 cm inner diameter, 690 mL), supplied with a measured CO-free air flow at approximately 110 mL/ min. After a 1-to 2-h equilibration period, the CO in the chamber outlet gas was determined by gas chromatography (t = 0 h). Each rat was then given an intraperitoneal injection of 30 pmol heme/ kg body weight. In addition, experimental rats were given 4 pmol metalloporphyrin/kg body weight, and the control rats received returned to their chambers, i n d the VeCO was determined every half hour for 6 h. At the completion of this procedure, animals were decapitated and the tissue HO activity was determined (see above).
In vitro photorc~uctivity. Photoreactive compounds have been found to photooxidize organic compounds to yield CO (14) . NADH, like NADPH, is one of the compounds that are particularly sensitive to degradation by this process. For this study, we determined the photoreactivity of metalloporphyrins in vitro by incubating 40 pM metalloporphyrin in 60 pL of 4.5 mM NADH (Sigma Chemical Co., St. Louis, MO) at 37°C in clear, septumsealed vials (2 mL). The vials were then exposed to cool white light (20 pW. ~m -~. nm-' or 30 W. m-2, see below) for 15 min. The generated CO was quantitated by injecting the vial headspace gas into a reduction gas analyzer (Trace Analytical, Inc., Menlo Park, CA). The results, corrected for dark control reactions determined simultaneously, were expressed in terms of pmol CO generated per vial per 15-min period.
In vivo phototoxicity. In vivo phototoxicity of the chromium and manganese metalloporphyrins was assessed as described earlier (15) . Metalloporphyrins at a dose of 40 pmol/kg body weight were administered to each of 12-to 24-h-old neonatal Wistar rats. Animals were placed three to a glass chamber (25 x . After completing the reaction, 1 mL of buffer was added, and the bilirubin concentration in the solution was measured with the spectrophotometric UB analyzer, UA-I (Arrows Co., Ltd., Osaka, Japan). Photodegradative loss of bilirubin was expressed as a percentage of dark controls and compared with bilirubin degradation in the absence of metalloporphyrin (light control). Light measuremmts. Radiance (pW. cm-*. nm-') was measured with a Mark I1 Bili-Meter (Olympic Medical, Seattle, WA) over the range of 425 to 475 nm. Light intensities were also determined with a model 2M thermopile detector with sapphire window and argon gas (Dexter Research Center, Dexter, MI). This detector has a flat spectral response from UV to far infrared and a linear signal output from lo-* to lo3 W. m-2.
Statistics. The data are presented as means + SD. The results of VeCO measurements were tested using the one-way factorial analysis of variance. All other experiments were evaluated by repeated-measures analysis of variance. The Scheffe F-test was considered significant at p < 0.05 as indicated by appropriate letters defined in each table and figure.
RESULTS
The results in Figure I show that, as expected, the reference compound, heme, served as the only effective substrate for the HO reaction. Ofthe other compounds tested, only the manganese porphyrins appeared to support observable but low-level CO production. However, the net CO production was due to suppression of CO production in the blank rather than an increase in CO production in the presence of NADPH, which is characteristic for HO substrates. Therefore, this CO production is not likely to be due to metabolism of the manganese porphyrins but is perhaps representative of an inhibitory effect on the as-yet- unidentified minor process that is responsible for C O production in the absence of NADPH. Figure 2 presents each metalloporphyrin's ability to photooxidize NADH and generate CO. The reference tin analogs were the most powerful photooxidizers, with SnPP evolving 350 pmol o f C O and SnMP over 500 pmol during the 15-min light exposure period. Magnesium porphyrin expressed only slight, but statistically significant, photoreactivity. Of the photoreactive porphyrins. the M P species appeared to be more reactive than the P P analogs, but the difference was not statistically significant. Zinc, manganese, chromium, and nickel compounds had no statistically significant photoreactivity as determined by this sensitive assay. Figure 3 presents the results of another index of photoreactivity, the enhancement of bilirubin degradation. Light exposure alone decreased the bilirubin concentration in the bilirubin/ human serum albumin to 79% of dark control (dashed line). Fig. 4 . Inhibition of HO with metalloporphyrins. Postmitochondrial supernatants prepared from the livers of fasted adult male Wistar rats were incubated with 40 pM of the indicated metalloporphyrin and HO assay reagents for 15 min at 37°C. The generated CO. representing HO activity, was measured by gas chromatography. All compounds significantly ( p < 0.05) inhibited the heme control reaction. Also significantly different were compounds labeled with a, when compared with all other inhibitors (n = 4).
only caused a decrease to about 67% of dark control. None of the other compounds significantly enhanced the photodegradation of bilirubin. These results parallel those found with the C O production assay shown in Figure 2 .
When rat neonates were treated intrapentoneally with 40 pmol each of CrPP, CrMP. MnPP, manganese mesoporphyrin, or SnPP, only the SnPP-treated animals suffered light-dependent death as has been shown previously ( 1 5, 16). These animals had symptoms as described previously and died within 4 h of the start of light exposure. None of the chromium-and manganeseporphyrin-treated animals died or showed any signs of observable adverse effects as described for SnPP (data not shown).
The ability of each metalloporphyrin to inhibit rat liver H O in vitro at the screening concentration of 40 pM is illustrated in Figure 4 . All metalloporphyrins inhibited H O activity to a significant extent. NiPP and MnPP were the least effective inhibitors in this series.
The results of the screening procedure indicated that the chromium metalloporphyrins were particularly attractive for further study. These compounds were not metabolized, did not VREMAN I:T .4I. cause photodestructive reactions. and potentlv inhibited HO. DISCUSSION Therefore. we investigated the efficacy -of Cr* and CrMP to inhibit rat liver and spleen HO in vitro over a range of concentrations. Furthermore. even though the manganese compounds appeared to have an effect on non-HO-related CO production. their total lack of photoreactivity made these compounds also attractive for some further in vitro efficacy study. Table 1 shows that there was significant, concentration-dependent inhibition at concentrations as low as 1 pM for all four compounds. In the case of the chromium compounds, the MP appeared to be more potent. Spleen HO activity is more completely inhibited by all four compounds than is liver HO activity.
The chromium analogues were additionally tested for their ability to inhibit bilirubin production and tissue HO activity in vivo. The results of CO excretion rate experiments with an iatrogenic hemolytic model, using adult male Wistar rats, are shown in Figure 5 . After injection of heme (30 pmol/kg body weight). the VeCO of each animal began to increase significantly to reach approximately four times the control rate by t = 4.5 h. However, the steep rise in VeCO observed in control animals was less steep in the animals simultaneously given an intraperitoneal dose of 4 pmol/kg body weight of either CrPP or CrMP.
As expected from the in virro tests performed earlier, the CrMP was a more powerful inhibitor of CO production than CrPP (significant only at t = 6 h), decreasing the maximum rate of CO production (recorded at t = 5.5 h after heme administration) to 58 and 79% of the total excretion CO rate. respectively, or 44 and 7276, respectively. of the CO excretion rate increase due to heme administration.
After 6 h of in vivo monitoring, the rats were killed and the livers. spleens, and brains were excised for determination of HO activity. As seen in Table 2 , the liver and spleen HO activity at t = 6 h after treatment was significantly lower in rats given either CrPP or CrMP. Again, the CrMP more potently inhibited HO than CrPP. However, the inhibitors did not appear to cross the blood-brain barrier. because no significant inhibition of brain HO was observed after the 6-h experimental time course.
The results of this investigation show that there exist effective synthetic metalloporphyrin HO inhibitors without photosensitizing properties. Thus, these compounds could be considered as alternative agents to the tin metalloporphyrins for suppressing the excessive neonatal jaundice often associated with hemolytic disease. Although phototoxicity is not likely to be the only side effect of these potential drugs, it remains one property that we believe may be significant to neonates receiving simultaneous light treatment. Several other side effects of metalloporphyrins have been reported (24), and the significance of these needs future attention.
The screening procedure also identified metalloporphyrins that were not metabolized to CO and other products that may be detrimental to the organism. Besides heme, the intended substrate for HO, only the manganese porphyrins appeared to be degraded to CO under HO assay reaction conditions. These findings were unexpected. Closer examination of the test results showed that it was the blank CO production that was suppressed by the presence of the manganese porphyrins. The CO production in the presence of NADPH was similar to that in the absence of any porphyrin or to that in the presence of non-manganesecontaining porphyrins, either in the presence or absence of NADPH. The blank reaction, for which the NADPH-containing reaction is corrected, represents a minor process of CO production which has not yet been identified. This process has not been previously observed to be affected by the presence of metalloporphyrin. It could possibly be related to lipid peroxidation processes, which we have found to generate CO as well as thiobarbituric acid-reactive substances (25). Maines and Kappas (18) found that metalloporphyrins (such as Mn-, Ni-, and SnPP), which do not bind molecular oxygen, cannot be substrates for HO. Although MnPP metabolism has been reported to occur in bacteria (26), there is no evidence of a similar process in mammals (27). If such a process exists, the administration of manganese porphyrins, either as HO inhibitors or as magnetic reso- S p < 0.05 compared with 0.1 pM.
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nance imaging contrast agents, needs to be approached with caution, because the Mn++ ion has been shown to be a cardiac toxin, and the LDSo for MnPP was found to be 0.19 + 0.01 m M (27). However, our in vivo phototoxicity test did not reveal evidence that manganese porphyrin administration had any noticeable side effects at the concentration tested (40 FM). No tests were performed to detect biochemical interferences by these compounds. Assessment ofthe photoreactivity of metalloporphyrins, determined from both the photogeneration of C O from NADH and the photodegradation of bilirubin, yielded similar results. Both procedures identified the tin porphyrins as potent photosensitizers. followed by the weaker NiPP. Magnesium PP and the zinc derivatives displayed very slight, but nonsignificant. photoreactivity in these tests. The reported photochemical behavior of zinc porphyrins is not entirely consistent, and ranges from no activity t o substantial in vitro photoreactivity (28, 29) . However. none of the in vivo studies with zinc P P have reported signs of toxicity, chemical or otherwise ( I I . 15. 16). The chromium and manganese porphyrins in this study also showed n o phototoxicity in vivo.
We have chosen to eliminate from consideration most (except possibly zinc deuteroporphyrin bis glycol) photosensitizing compounds because their risk of side effects may not outweigh the benefit of the drug. However, this property may be used in other clinical contexts, c .~. in the localization and photodynamic treatment of neoplastic tissues (13) and psoriasis (30) . Perhaps, for these purposes. one would select metalloporphyrins with poor H O inhibition and favorable paramagnetic, pharmacokinetic. and photochemical properties.
In this study, the metalloporphyrins were administered intraperitoneally, because earlier studies have shown that most metalloporphyrins are not readily absorbed when administered orally (31, 32) . However, Vallier et al. recently showed that the readily soluble zinc deuteroporphyrin bis glycol (33) and CrMP (34) were absorbed enterally by neonatal rats and subsequently inhibited H O activity in liver and spleen. Enteral absorptivity will be a highly desirable quality for an H O inhibitor intended to inhibit systemic as well as enteral H O (35) . The results in Table 2 indicate that brain H O activity was not inhibited after intraperitoneal administration of CrPP or CrMP. This is most likely due to the impermeability of the blood brain bamer to those compounds, because HO-2, the predominant isoform in the brain, is inhibitable in vitro by metalloporphyrins (36) . Only SnPP has been reported to cross the blood-brain barrier and inhibit H O activity in vivo (37) .
We have chosen the hemolytic model to study the effect of metalloporphyrins, because it is the hyperbilirubinemia caused by hemolysis that needs to be reduced in human neonates (4) . Furthermore, we believe that tissue HO, even though it is the rate-limiting enzyme in the heme-degrading pathway, usually occurs in excess relative to the heme available. Thus. in the present rat model most if not all H O is engaged in the degradation of heme, and it is important to study the effect of metalloporphyrins under this condition.
In summary. the results of this study show that CrPP and CrMP are potent H O inhibitors without photoreactive properties. This combination of characteristics makes these compounds attractive for further evaluation as possible agents for the prevention of excessive neonatal jaundice caused by hemolysis. 
